Erasca Partners With Bristol Myers Squibb on Pancreatic Cancer Drug Trial
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
11:41:46 PM UTC
SquawkNews
ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trialBMS will sponsor the clinical trial and Erasca will supply ERAS-0015SAN DIEGO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. NASDAQ:ERAS, a clinical-stage precision oncology company s…